Overview: Leishmania RK39 Antibody TestIntroduction: The Leishmania RK39 Antibody Test detects Leishmania RK-39 antibodies to diagnose kala-azar, causing spleen enlargement or fever. Following 2023 WHO guidelines, it uses immunoassay for high specificity, supporting parasite screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in parasitology for patients with suspected visceral leishmaniasis.
Other Names: Leishmania RK-39 Assay, Kala-Azar Rapid Test.
FDA Status: Laboratory-developed test (LDT), meeting parasitology standards for diagnostic accuracy.
Historical Milestone: RK-39 antibody testing emerged in the 1990s with kala-azar research. Immunoassay methods improved in the 2000s, enhancing rapid diagnostic precision.
Purpose: Detects Leishmania RK-39 antibodies to diagnose kala-azar, guides treatment, and evaluates patients with spleen enlargement or fever.
Test Parameters: 1. Leishmania RK-39 Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of spleen enlargement, fever, or weight loss.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document spleen enlargement, fever, weight loss, or travel history to leishmaniasis-endemic areas. Include current medications, especially antiparasitics.
Consent: Written consent required, detailing the tests purpose, kala-azar implications, and risks of blood or saliva collection.
Procedural Considerations: Uses rapid immunoassay to detect Leishmania RK-39 antibodies in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for kala-azar diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Early infection may yield false negatives.
Clinical Significance: Positive RK-39 antibodies confirm kala-azar, guiding antiparasitic therapy. Negative results may require PCR or further testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: Leishmania IgG test, bone marrow biopsy, or PCR to confirm kala-azar diagnosis.
Test Limitations: Highly specific to visceral leishmaniasis but may miss early infection. Clinical correlation is needed.
References: WHO Leishmaniasis Guidelines, 2023; The Lancet Infectious Diseases, Alvar J, 2022.
